Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Andersen Group (NYSE:ANDG), Biohaven (NYSE:BHVN)

Core Viewpoint - U.S. stock futures showed mixed results, with Dow futures declining approximately 0.1% as Biohaven Ltd's shares fell sharply following disappointing trial results for its depression drug [1] Company-Specific Summary - Biohaven Ltd (NYSE:BHVN) reported that its investigational drug BHV-7000 for major depressive disorder did not meet its primary endpoint in a six-week trial, failing to show a significant reduction in depressive symptoms compared to placebo, as measured by the Montgomery Åsberg Depression Rating Scale [2] - Following the announcement, Biohaven's shares dropped 14.3% to $9.27 in pre-market trading [2] Other Stocks Movement - Heartland Express Inc (NASDAQ:HTLD) saw a decline of 8.9% to $8.40 in pre-market trading after declaring a regular quarterly cash dividend of 2 cents per share [3] - Omeros Corp (NASDAQ:OMER) decreased by 6.8% to $14.32 in pre-market trading, despite a previous surge of over 75% after FDA approval of YARTEMLEA for a specific medical condition [3] - Andersen Group Inc (NYSE:ANDG) fell 4.6% to $24.30 in pre-market trading after a prior gain of 4% [3] - PennyMac Mortgage Investment Trust (NYSE:PMT) declined 2.8% to $12.67, while Black Rock Coffee Bar Inc (NASDAQ:BRCB) and Lifestance Health Group Inc (NASDAQ:LFST) both fell by 2.7% to $22.70 and $6.90 respectively [3] - Kyverna Therapeutics Inc (NASDAQ:KYTX) experienced a decrease of 2.6% to $8.76 in pre-market trading [3]